Lotrafiban hydrochloride
| Code | Size | Price |
|---|
| TAR-T27846-5mg | 5mg | £1,010.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27846-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27846-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lotrafiban hydrochloride is an platelet glycoprotein IIb/IIIa blocker with oral activity.
CAS:
179599-82-7
Formula:
C23H33ClN4O4
Molecular Weight:
464.99
Purity:
0.98
SMILES:
Cl.CN1Cc2cc(ccc2N[C@@H](CC(O)=O)C1=O)C(=O)N1CCC(CC1)C1CCNCC1
References
1. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29;108(4):399-406. Epub 2003 Jul 21. PubMed PMID: 12874182
2. Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis. Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):13-25. PubMed PMID: 12769654.
3. Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA. Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb Res. 2001 Jul 15;103(2):143-8. PubMed PMID: 11457472.
4. Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther. 2001 Apr;69(4):210-22. PubMed PMID: 11309549.